Detalhe da pesquisa
1.
The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis.
Mol Cells
; 46(3): 176-186, 2023 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36994476
2.
The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner.
Antioxidants (Basel)
; 12(1)2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36670978
3.
The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer.
Sci Rep
; 12(1): 293, 2022 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34997154
4.
Potential therapeutic uses of rexinoids.
Adv Pharmacol
; 91: 141-183, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34099107
5.
The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer.
Cancers (Basel)
; 13(19)2021 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638488
6.
Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice.
Sci Rep
; 11(1): 1234, 2021 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33441637
7.
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
Sci Rep
; 10(1): 22244, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335263
8.
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models.
NPJ Breast Cancer
; 5: 39, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31700995